| Doctorant : | Camille JUBELIN |
| Directeur de thèse : | Dominique HEYMANN , Professeur - Praticien Hospitalier Université |
| co-directeur de thèse : | OLIVER Lisa |
| Financement : | |
| Date de la soutenance : | mardi 27 juin 2023, 13h30 |
| Modalité : | |
| Jury : |
|
Publications
2022
Jubelin, Camille; Muñoz-Garcia, Javier; Griscom, Laurent; Cochonneau, Denis; Ollivier, Emilie; Heymann, Marie-Françoise; Vallette, François M; Oliver, Lisa; Heymann, Dominique
Three-dimensional in vitro culture models in oncology research Article de journal
Dans: Cell Biosci, vol. 12, no. 1, p. 155, 2022, ISSN: 2045-3701.
@article{pmid36089610,
title = {Three-dimensional in vitro culture models in oncology research},
author = {Camille Jubelin and Javier Muñoz-Garcia and Laurent Griscom and Denis Cochonneau and Emilie Ollivier and Marie-Françoise Heymann and François M Vallette and Lisa Oliver and Dominique Heymann},
doi = {10.1186/s13578-022-00887-3},
issn = {2045-3701},
year = {2022},
date = {2022-09-01},
urldate = {2022-09-01},
journal = {Cell Biosci},
volume = {12},
number = {1},
pages = {155},
abstract = {Cancer is a multifactorial disease that is responsible for 10 million deaths per year. The intra- and inter-heterogeneity of malignant tumors make it difficult to develop single targeted approaches. Similarly, their diversity requires various models to investigate the mechanisms involved in cancer initiation, progression, drug resistance and recurrence. Of the in vitro cell-based models, monolayer adherent (also known as 2D culture) cell cultures have been used for the longest time. However, it appears that they are often less appropriate than the three-dimensional (3D) cell culture approach for mimicking the biological behavior of tumor cells, in particular the mechanisms leading to therapeutic escape and drug resistance. Multicellular tumor spheroids are widely used to study cancers in 3D, and can be generated by a multiplicity of techniques, such as liquid-based and scaffold-based 3D cultures, microfluidics and bioprinting. Organoids are more complex 3D models than multicellular tumor spheroids because they are generated from stem cells isolated from patients and are considered as powerful tools to reproduce the disease development in vitro. The present review provides an overview of the various 3D culture models that have been set up to study cancer development and drug response. The advantages of 3D models compared to 2D cell cultures, the constraint, and the fields of application of these models and their techniques of production are also discussed.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Cancer is a multifactorial disease that is responsible for 10 million deaths per year. The intra- and inter-heterogeneity of malignant tumors make it difficult to develop single targeted approaches. Similarly, their diversity requires various models to investigate the mechanisms involved in cancer initiation, progression, drug resistance and recurrence. Of the in vitro cell-based models, monolayer adherent (also known as 2D culture) cell cultures have been used for the longest time. However, it appears that they are often less appropriate than the three-dimensional (3D) cell culture approach for mimicking the biological behavior of tumor cells, in particular the mechanisms leading to therapeutic escape and drug resistance. Multicellular tumor spheroids are widely used to study cancers in 3D, and can be generated by a multiplicity of techniques, such as liquid-based and scaffold-based 3D cultures, microfluidics and bioprinting. Organoids are more complex 3D models than multicellular tumor spheroids because they are generated from stem cells isolated from patients and are considered as powerful tools to reproduce the disease development in vitro. The present review provides an overview of the various 3D culture models that have been set up to study cancer development and drug response. The advantages of 3D models compared to 2D cell cultures, the constraint, and the fields of application of these models and their techniques of production are also discussed.
Jubelin, Camille; Cochonneau, Denis; Moranton, Emilie; Munoz-Garcia, Javier; Heymann, Dominique
Circulating Tumor Cells and ctDNA in Sarcomas Chapitre d'ouvrage
Dans: Leong, Stanley P.; Nathanson, S. David; Zager, Jonathan S. (Ed.): Cancer Metastasis Through the Lymphovascular System, p. 121–128, Springer, 2022.
@inbook{jubelin2022circulating,
title = {Circulating Tumor Cells and ctDNA in Sarcomas},
author = {Camille Jubelin and Denis Cochonneau and Emilie Moranton and Javier Munoz-Garcia and Dominique Heymann},
editor = {Stanley P. Leong and S. David Nathanson and Jonathan S. Zager},
doi = {10.1007/978-3-030-93084-4_12},
year = {2022},
date = {2022-06-25},
urldate = {2022-06-25},
booktitle = {Cancer Metastasis Through the Lymphovascular System},
pages = {121--128},
publisher = {Springer},
abstract = {Sarcomas are clustered in two oncological entities named bone and soft tissue sarcomas. Both are rare cancers originating from the mesenchyme, characterized by their propensity to induce the development of lung metastases. Sarcoma cells escaping from the primary tumor site spread to the pulmonary tissue through the bloodstream where they found a favorable microenvironment to establish metastatic foci. The low number of patients, the high histological, genetic, and molecular heterogeneity of sarcomas combined with the absence of specific markers expressed by cancer cells make the detection and follow-up of the minimal residual disease challenging. Over the last decade, tremendous technological progress has been made towards the detection of recurrent diseases. The literature is now enriched of information describing the use of liquid biopsies in clinical care of sarcoma patients. This chapter aims to give a brief overview of the most recent data available on the detection of circulating tumor cells and circulating tumor DNA in sarcomas.},
keywords = {},
pubstate = {published},
tppubtype = {inbook}
}
Sarcomas are clustered in two oncological entities named bone and soft tissue sarcomas. Both are rare cancers originating from the mesenchyme, characterized by their propensity to induce the development of lung metastases. Sarcoma cells escaping from the primary tumor site spread to the pulmonary tissue through the bloodstream where they found a favorable microenvironment to establish metastatic foci. The low number of patients, the high histological, genetic, and molecular heterogeneity of sarcomas combined with the absence of specific markers expressed by cancer cells make the detection and follow-up of the minimal residual disease challenging. Over the last decade, tremendous technological progress has been made towards the detection of recurrent diseases. The literature is now enriched of information describing the use of liquid biopsies in clinical care of sarcoma patients. This chapter aims to give a brief overview of the most recent data available on the detection of circulating tumor cells and circulating tumor DNA in sarcomas.
Jubelin, Camille; Munoz-Garcia, Javier; Cochonneau, Denis; Moranton, Emilie; Heymann, Marie Françoise; Heymann, Dominique
Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma Article de journal
Dans: Cancer Drug Resistance, vol. 5, iss. 5, p. 184-198, 2022.
@article{jubelin2022biological,
title = {Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma},
author = {Camille Jubelin and Javier Munoz-Garcia and Denis Cochonneau and Emilie Moranton and Marie Françoise Heymann and Dominique Heymann},
doi = {10.20517/cdr.2021.130},
year = {2022},
date = {2022-02-16},
urldate = {2022-02-16},
journal = {Cancer Drug Resistance},
volume = {5},
issue = {5},
pages = {184-198},
abstract = {Sarcomas are a large family of cancers originating in the mesenchyme. Composed of more than 100 histological subtypes, soft tissue and bone sarcomas remain clinically challenging, particularly in children and adolescents in whom sarcomas are the second most common malignant entities. Osteosarcoma is the main primary bone tumor in adolescents and young adults and is characterized by a high propensity to induce distant metastatic foci and become multi-drug resistant. The innate and acquired resistance of osteosarcoma can be explained by high histological heterogeneity and genetic/molecular diversity. In the last decade, the notion of cancer stem-like cells (CSCs) has emerged. This subset of cancer cells has been linked to drug resistance properties, recurrence of the disease, and therapeutic failure. Although CSCs remain controversial, many elements are in favor of them playing a role in the development of the drug resistance profile. The present review gives a brief overview of the most recent biological evidence of the presence of CSCs in osteosarcomas and their role in the drug resistance profile of these rare oncological entities. Their use as promising therapeutic targets is discussed.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Sarcomas are a large family of cancers originating in the mesenchyme. Composed of more than 100 histological subtypes, soft tissue and bone sarcomas remain clinically challenging, particularly in children and adolescents in whom sarcomas are the second most common malignant entities. Osteosarcoma is the main primary bone tumor in adolescents and young adults and is characterized by a high propensity to induce distant metastatic foci and become multi-drug resistant. The innate and acquired resistance of osteosarcoma can be explained by high histological heterogeneity and genetic/molecular diversity. In the last decade, the notion of cancer stem-like cells (CSCs) has emerged. This subset of cancer cells has been linked to drug resistance properties, recurrence of the disease, and therapeutic failure. Although CSCs remain controversial, many elements are in favor of them playing a role in the development of the drug resistance profile. The present review gives a brief overview of the most recent biological evidence of the presence of CSCs in osteosarcomas and their role in the drug resistance profile of these rare oncological entities. Their use as promising therapeutic targets is discussed.
Lien
